First in Patient Study for PF-06840003 in Malignant Gliomas

PHASE1TerminatedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

September 9, 2016

Primary Completion Date

December 26, 2018

Study Completion Date

December 26, 2018

Conditions
OligodendrogliomaAstrocytomaMalignant Glioma
Interventions
DRUG

PF-06840003

Daily Oral PF-06840003

Trial Locations (14)

10019

Columbia University Medical Center, New York

10032

Columbia University Medical Center, New York

CUMC Research Pharmacy, New York

10591

Columbia Doctors Tarrytown, Tarrytown

27710

Duke Cancer Center, Durham

Duke University Medical Center, Duke Cancer Center, Durham

87102

University of New Mexico Comprehensive Cancer Center, Albuquerque

90095

UCLA Clinical & Translational Research Center, Los Angeles

UCLA Oncology Center, Los Angeles

UCLA School of Medicine, Los Angeles

90095-6894

Ronald Reagan UCLA Medical Center, Los Angeles

02114

Massachusetts General Hospital, Boston

02115

Brigham & Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY